Key Points
- Insider sale: Director Paul Rubin sold 18,000 shares on Dec. 9 at an average price of $12.00, totaling $216,000, according to an SEC Form 4 filing.
- Stock and results: BIOA opened at $12.59 (50‑day MA $7.87; 1‑year range $2.88–$13.10) and reported Q3 EPS of ($0.56), beating estimates by $0.11, on $2.05 million of revenue.
- Market sentiment is mixed: Citigroup upgraded to a Buy with a $15 target while Weiss Ratings kept a Sell, leaving a consensus Hold and $15 average target, and several hedge funds (including Vanguard, Geode and Millennium) have recently increased positions.
BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) insider Paul Rubin sold 18,000 shares of the business's stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $12.00, for a total value of $216,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
BioAge Labs Price Performance
Shares of NASDAQ:BIOA opened at $12.59 on Friday. The firm's fifty day moving average is $7.87. The company has a market capitalization of $451.17 million, a P/E ratio of -8.28 and a beta of 1.74. BioAge Labs, Inc. has a 1-year low of $2.88 and a 1-year high of $13.10.
BioAge Labs (NASDAQ:BIOA - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on BIOA. Weiss Ratings reissued a "sell (d-)" rating on shares of BioAge Labs in a report on Thursday, October 30th. Citigroup increased their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of BioAge Labs from a "sell" rating to a "hold" rating in a research report on Saturday, December 6th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $15.00.
Check Out Our Latest Analysis on BioAge Labs
Hedge Funds Weigh In On BioAge Labs
A number of hedge funds have recently modified their holdings of BIOA. Vanguard Group Inc. increased its stake in shares of BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company's stock worth $9,709,000 after purchasing an additional 93,694 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company's stock valued at $1,873,000 after buying an additional 171,426 shares in the last quarter. Millennium Management LLC boosted its holdings in BioAge Labs by 749.8% in the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company's stock worth $1,803,000 after buying an additional 270,479 shares during the period. Marshall Wace LLP increased its stake in BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company's stock worth $937,000 after buying an additional 173,388 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its stake in BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company's stock worth $624,000 after buying an additional 101,085 shares in the last quarter.
About BioAge Labs
(
Get Free Report)
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
